Thymostimulin in malignant pleural effusions.
Twelve patients were admitted to the trial: 1 primary pleural tumour (mesothelioma), 7 metastases of breast carcinoma, 1 lung epidermoid, 1 lung adenocarcinoma, 1 uterine carcinoma, and 1 ovarian carcinoma. Thymostimulin (TS) was injected intrapleurally at the mean dose of 140 mg (2 mg/kg). The mesothelioma was the only resistant case. Complete remission was obtained in 4 patients after 3 weeks and in 4 within 8 weeks of treatment. This preliminary trial has shown that intrapleural treatment of neoplastic pleural effusion with a thymic hormone preparation can induce rapid and efficient palliation without subjecting the patients to distressing or toxic procedures.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy; D008875:Middle Aged; D010166:Palliative Care; D010996:Pleural Effusion / Q000276:immunology; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000556:secondary; D013601:T-Lymphocytes / Q000276:immunology; D013949:Thymus Extracts / Q000627:therapeutic use*
D013949:Thymus Extracts; C031407:thymostimulin